文献速递垂体与肾上腺疾病

肢端肥大症临床与病理谱:区分GH PitNETs、 mammosomatotrophs和混合瘤

Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

该研究通过双免疫荧光定量51例肢端肥大症患者的GH和PRL表达,比较GH PitNETs、mammosomatotrophs和混合SL PitNETs的临床与分子差异。结果显示mammosomatotrophs的PRL水平显著更高,41%的PRL阳性肿瘤无高泌乳素血症,混合SL PitNETs的SSTR2表达降低,GH PitNETs的SSTR5较高,且所有缺乏细胞角蛋白表达的肿瘤对药物治疗无反应。

要点

  • mammosomatotrophs患者PRL水平显著更高,但肿瘤大小和侵袭性无差异。
  • 41%的PRL阳性肿瘤无高泌乳素血症,为静默性PRL阳性GH PitNETs。
  • 混合SL PitNETs的SSTR2表达降低,可能对SSTR配体反应较差。

核心结论

  • GH&PRL PitNETs存在异质性,包括静默性PRL阳性GH PitNETs。
  • 混合SL肿瘤可能对SSTR配体反应较差,需基于肿瘤亚型和受体谱制定个体化策略。

研究设计与样本

  • 对51例肢端肥大症患者的PitNETs(23例GH PitNETs、20例mammosomatotrophs、8例混合SL PitNETs)进行双免疫荧光定量GH和PRL表达。
  • 将表达结果与临床数据及组织学标志物(SSTR2、SSTR3、SSTR5、E-cadherin、CAM 5.2)进行相关性分析。

主要发现

  • GH PitNETs与混合SL PitNETs的GH或IGF-1水平无显著差异。
  • mammosomatotrophs的PRL水平显著更高。
  • 两组肿瘤大小和侵袭性相当。
  • 41%的PRL阳性肿瘤无高泌乳素血症。
  • 混合SL PitNETs的SSTR2表达降低,GH PitNETs的SSTR5水平较高。

关键数值与推荐

  • 41%的PRL阳性肿瘤无高泌乳素血症。
  • 混合SL PitNETs显示SSTR2表达降低。
  • GH PitNETs显示较高的SSTR5水平。
  • 所有缺乏细胞角蛋白表达的肿瘤对药物治疗无反应。

临床怎么用

  • 对肢端肥大症患者应评估肿瘤亚型及受体谱(SSTR2、SSTR5、细胞角蛋白)。
  • PRL阳性但无高泌乳素血症者需考虑静默性PRL阳性GH PitNETs。
  • 混合SL PitNETs可能对SSTR配体反应较差,需个体化治疗。
  • 细胞角蛋白表达缺失提示对药物治疗无反应,应尽早考虑其他治疗方式。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acromegaly is a rare disease usually caused by a pituitary neuroendocrine tumor (PitNET) that produces GH PitNET. PitNETs secreting GH and prolactin (GH&PRL PitNETs) contribute up to 30% to the spectrum of acromegaly and have been attributed a more aggressive behavior. GH&PRL PitNETs can be classified into 2 predominant phenotypes: mammosomatotroph arising from a single-cell population of Pit-1 lineage and mixed somatotroph-lactotroph PitNETs (mixed SL PitNETs). PURPOSE: To evaluate the clinical and molecular differences between GH PitNETs, mammosomatotroph, and mixed SL PitNETs. METHODS: We quantified GH and PRL expression by double immunofluorescence in 51 PitNETs (23 GH PitNETs, 20 mammosomatotrophs, and 8 mixed SL PitNETs) from patients with acromegaly. These findings were correlated with clinical data and histologic markers such as somatostatin receptor (SSTR)2, SSTR3, SSTR5, E-cadherin, and CAM 5.2. RESULTS: Our results did not reveal significant differences in GH or IGF-1 levels between GH PitNETs and mixed SL PitNETs, but PRL levels were significantly higher in mammosomatotrophs. Tumor size and invasiveness were comparable between the 2 groups. Interestingly, 41% of prolactin (PRL)-positive tumors did not show hyperprolactinemia, representing silent PRL-positive GH PitNETs. Mixed SL PitNETs exhibited reduced SSTR2 expression, while GH PitNETs exhibited higher SSTR5 levels. Moreover, all tumors lacking cytokeratin expression were nonresponders to medical therapy. CONCLUSION: These findings highlight the heterogeneity within GH&PRL PitNETs, including silent PRL-positive GH PitNETs. Our data suggest mixed SL tumors may be less responsive to SSTR ligands, emphasizing the need for tailored strategies based on tumor subtype and receptor profile.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Martínez-Hernández R, Méndez-García FF, Serrano-Somavilla A, et al. Clinical and Pathological Spectrum of Acromegaly: Distinguishing GH PitNETs, Mammosomatotrophs, and Mixed Tumors. J Clin Endocrinol Metab. 2026. PMID: 41296644. doi:10.1210/clinem/dgaf634

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。